📊 SYRE Key Takeaways
Is Spyre Therapeutics, Inc. (SYRE) a Good Investment?
Spyre Therapeutics is a pre-revenue pharmaceutical company with zero revenue generation and quarterly cash burn of $57.4M against only $97.2M in cash reserves, providing approximately 1.7 quarters of runway. While the balance sheet shows minimal debt and strong equity position ($670.8M), the company faces imminent financing risk as operational losses (-$69.0M net loss latest period) are consuming capital with no offsetting revenue generation.
Spyre Therapeutics, Inc. Key Strengths (SYRE)
- Minimal debt with 0.00x Debt/Equity ratio and strong stockholders equity of $670.8M
- Excellent liquidity position with 8.97x current ratio providing near-term operational flexibility
- Substantial asset base of $764.0M providing financial cushion for development activities
- Insider activity with 9 Form 4 filings suggesting some level of insider confidence
SYRE Stock Risks: Spyre Therapeutics, Inc. Investment Risks
- Zero revenue generation typical of pre-clinical/early-stage biotech with no clear path to commercialization
- Severe quarterly cash burn of $57.4M with only ~1.7 quarters of runway remaining before liquidity crisis
- Large operating and net losses (-$45.6M and -$69.0M respectively) with negative ROE (-10.3%) and ROA (-9.0%)
- High execution risk dependent on successful clinical trial outcomes and FDA approval with no guaranteed success
- Imminent need for capital raise or major revenue milestone within 6 months to avoid financial distress
Key Metrics to Watch
- Cash balance and burn rate trends quarterly to monitor runway sufficiency
- Clinical trial progress and FDA milestone achievements for pipeline candidates
- Capital raising activities and any strategic partnerships or licensing deals
- Path to revenue generation timeline and commercial milestone achievements
Spyre Therapeutics, Inc. (SYRE) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 8.97x current ratio provides a solid financial cushion.
SYRE Profit Margin, ROE & Profitability Analysis
SYRE vs Healthcare Sector: How Spyre Therapeutics, Inc. Compares
How Spyre Therapeutics, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Spyre Therapeutics, Inc. Stock Overvalued? SYRE Valuation Analysis 2026
Based on fundamental analysis, Spyre Therapeutics, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Spyre Therapeutics, Inc. Balance Sheet: SYRE Debt, Cash & Liquidity
SYRE Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Spyre Therapeutics, Inc.'s revenue has declined by 95% over the 5-year period, indicating business contraction. The most recent EPS of $-25.02 indicates the company is currently unprofitable.
SYRE Revenue Growth, EPS Growth & YoY Performance
SYRE Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2024 | N/A | -$18.4M | $-1.36 |
| Q2 2024 | N/A | -$18.4M | $-0.86 |
| Q1 2024 | N/A | -$18.4M | $-1.20 |
| Q3 2023 | N/A | -$18.2M | $-4.84 |
| Q2 2023 | $625.0K | -$18.4M | $-0.27 |
| Q1 2023 | $198.0K | -$18.4M | $-0.20 |
| Q3 2022 | $174.0K | -$6.8M | $-0.19 |
| Q2 2022 | $625.0K | -$6.8M | $-0.10 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Spyre Therapeutics, Inc. Dividends, Buybacks & Capital Allocation
SYRE SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Spyre Therapeutics, Inc. (CIK: 0001636282)
📋 Recent SEC Filings
❓ Frequently Asked Questions about SYRE
What is the AI rating for SYRE?
Spyre Therapeutics, Inc. (SYRE) has an AI grade of D with 85% confidence, based on fundamental analysis of SEC EDGAR filings.
What are SYRE's key strengths?
Claude: Minimal debt with 0.00x Debt/Equity ratio and strong stockholders equity of $670.8M. Excellent liquidity position with 8.97x current ratio providing near-term operational flexibility.
What are the risks of investing in SYRE?
Claude: Zero revenue generation typical of pre-clinical/early-stage biotech with no clear path to commercialization. Severe quarterly cash burn of $57.4M with only ~1.7 quarters of runway remaining before liquidity crisis.
What is SYRE's revenue and growth?
Spyre Therapeutics, Inc. reported revenue of $0.0.
Does SYRE pay dividends?
Spyre Therapeutics, Inc. does not currently pay dividends.
Where can I find SYRE SEC filings?
Official SEC filings for Spyre Therapeutics, Inc. (CIK: 0001636282) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is SYRE's EPS?
Spyre Therapeutics, Inc. has a diluted EPS of $-0.74.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.
What is SYRE's fundamental grade?
Based on our AI fundamental analysis in June 2026, Spyre Therapeutics, Inc. has a D grade with 85% confidence. Review the strengths and risks sections above for full context. This is not investment advice.
Is SYRE stock overvalued or undervalued?
Valuation metrics for SYRE: ROE of -10.3% (sector avg: 15%), net margin of N/A (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
What is SYRE's AI grade for 2026?
Our dual AI analysis gives Spyre Therapeutics, Inc. a combined D grade for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is SYRE's free cash flow?
Spyre Therapeutics, Inc.'s operating cash flow is $-57.4M, with capital expenditures of $0.0.
How does SYRE compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin N/A (avg: 12%), ROE -10.3% (avg: 15%), current ratio 8.97 (avg: 2).